Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | CCR2 | P41597 | 3/20 | 0.50 |
| ▸ | TACR1 | P25103 | 15/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863239 | 0.80 | KCNH2 (0.63) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13645885 | 0.80 | KCNH2 (0.63) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13645882 | 0.80 | KCNH2 (0.63) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13887072 | 0.77 | KCNH2 (0.48) | KCNH2CCR2TACR1KDM4EMEN1 | |
| SCHEMBL21065308 | 0.77 | KDM1A (0.44) | CCR2 | |
| SCHEMBL23938457 | 0.75 | TACR1 (0.42) | KCNH2CCR2TACR1KDM4EMEN1 | |
| SCHEMBL18244998 | 0.74 | TACR1 (0.46) | KCNH2CCR2TACR1CCR1KDM4E | |
| SCHEMBL5767429 | 0.74 | TACR1 (0.64) | KCNH2TACR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL6494230 | 0.74 | TACR1 (0.64) | KCNH2TACR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL5767423 | 0.74 | TACR1 (0.64) | KCNH2TACR1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | KCNH2 2543/4885CCR2 3/4885TACR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.